Liquidia Jumps After Settling Legal Dispute
Liquidia shares surged after settling a years-long legal dispute with United Therapeutics over its lung disease drug. The agreement removes a major litigation risk and ends six lawsuits. Liquidia will pay about $380.7 million while continuing sales for pulmonary arterial hypertension.
Xurve View
Insights:
Xurve View
LIQUIDIA CORP shares jumped 26% on Wednesday after settling a legal dispute with UNITED THERAPEUTICS CORP over its lung disease drug. The agreement ends six lawsuits over patents and trade secrets related to the dry-powder treatment Yutrepia. The resolution removes a major litigation overhang that had previously depressed the drugmaker's valuation by more than half following an adverse court ruling last month.
